Abstract

BackgroundLeucine-rich-alpha-2-glycoprotein 1 (LRG1) has been reported to be involved in several tumors, whether it participates in colorectal cancer (CRC) progression remains unclear. Here, we investigated the biological function and underlying molecular mechanisms of LRG1 in CRC.MethodsThe mRNA and protein levels of LRG1 were assessed in CRC tissues through RT-PCR and immunohistochemistry, respectively. HCT116 and SW480 cells were treated with LRG1 siRNA, control siRNA, or recombinant LRG1. Transwell invasion assays and wound healing assays were performed to evaluate the invasion and migration of CRC cells. Epithelial-to-mesenchymal transition (EMT) markers of E-cadherin, VDR, N-cadherin, α-SMA, Vimentin and Twist1 were detected by RT-PCR and western blot. Enzyme-linked immunosorbent assay was used to measure the secretion level of VEGF-A. Conditioned medium from CRC cells was collected for endothelial cell migration, tube formation and aortic ring sprouting assays.ResultsLRG1 was overexpressed in CRC tissues and associated with cancer aggressiveness. LRG1 was further found to induce the EMT process, as well as CRC cell migration and invasion capacity. In addition, LRG1 promoted VEGF-A expression in CRC cells and contributed to tumor angiogenesis. Furthermore, HIF-1α could be induced by LRG1 in a concentration- and time-dependent manner, which was responsible for LRG1-induced VEGF-A expression and EMT.ConclusionsThe present study suggests that LRG1 plays a crucial role in the progression of CRC by regulating HIF-1α expression, thereby may be a promising therapeutic target of CRC.

Highlights

  • Leucine-rich-alpha-2-glycoprotein 1 (LRG1) has been reported to be involved in several tumors, whether it participates in colorectal cancer (CRC) progression remains unclear

  • Positive staining of LRG1 was mainly distributed in the cytoplasm and cytomembrane of CRC cells (Fig. 1c)

  • Our study revealed that treatment of CRC cells with rLRG1 induced the expression of critical proangiogenic molecules including hypoxia-inducible factor-1α (HIF-1α) and vascular endothecial growth factor A (VEGF-A)

Read more

Summary

Introduction

Leucine-rich-alpha-2-glycoprotein 1 (LRG1) has been reported to be involved in several tumors, whether it participates in colorectal cancer (CRC) progression remains unclear. We investigated the biological function and underlying molecular mechanisms of LRG1 in CRC. Leucine-rich-alpha-2-glycoprotein (LRG1) is the founding member of leucine-rich repeat (LRR) family, which was first isolated from human serum in 1977 [2]. It is a secreted glycoprotein and contains eight repeating consensus sequences, each of which consists of 24 amino acid residues [3]. LRG1 has been reported to be involved in immune response, cell proliferation, cell migration, cell apoptosis and neovascularization [4,5,6,7]. It was reported that LRG1 was a target of miR-335 and contribute to the migratory and invasive

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call